Oncolytics Biotech, Inc. ONCY 深 滬
已收盤 09-19 16:00:00 美东时间
0.95
+0.020
+2.15%
華盛通- 最 高0.97
- 今 開0.94
- 成交量 22.97万股
- 最 低 0.9201
- 昨 收 0.93
- 總市值 6970.04万
- 52周最高 2.30
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 0.85
- 委 比 -72.75%
- 總股本 7336.88万
- 歷史最高 6.037
- 量 比 1.38
- 振 幅 5.37%
- 歷史最低 0.351
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oncolytics Biotech’s Promising Breast Cancer Study
Oncolytics Biotech (TSE:ONC) has released an update. Oncolytics Biotech has ann...
09-19 19:27
Sernova names Rigby as new CEO
Sernova (OTCQB:SEOVF) said it has appointed Jonathan Rigby as its new CEO. Rigby has helmed several companies, and currently serves on the board of directors of cancer therapy company, Oncolytics Biot...
08-12 19:52
RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target
RBC Capital analyst Douglas Miehm reiterates Oncolytics Biotech (TSX:ONC) with a Outperform and maintains C$6 price target.
08-05 23:18
Oncolytics Biotech Announces Equity Distribution Deal
Oncolytics Biotech (TSE:ONC) has released an update. Oncolytics Biotech Inc. ha...
08-03 05:27
Oncolytics Biotech’s Financials Show Asset Decline
Oncolytics Biotech (TSE:ONC) has released an update. Oncolytics Biotech Inc. re...
08-02 05:19
Oncolytics Biotech Q2 GAAP EPS $(0.07), Inline
Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year.
08-02 04:17
Oncolytics Biotech Advances Towards Drug Trial
Oncolytics Biotech (TSE:ONC) has released an update. Oncolyics Biotech has anno...
06-27 19:51
Oncolytics Biotech CEO Takes Medical Leave
Oncolytics Biotech (TSE:ONC) has released an update. Oncolytics Biotech announc...
06-24 19:51
Oncolytics Biotech Shareholders Approve Board
Oncolytics Biotech (TSE:ONC) has released an update. Oncolytics Biotech Inc. an...
05-16 19:49
Oncolytics Biotech Enters Preliminary Collaboration With The Global Coalition For Adaptive Research
The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's
05-15 19:08
